Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2014

Summary of Significant Accounting Policies

Analysis of U.S. product sales allowances and accruals

        An analysis of our U.S. product sales allowances and accruals for the years ended December 31, 2014, 2013 and 2012 is as follows (in thousands):

	Years Ended December 31,
	2014			2013			2012
Provision for U.S. product sales allowances and accruals
Discounts and chargebacks	$	55,420		$	37,098		$	26,517
Government and other rebates		25,091			10,868			6,058
Medicaid rebate reserve adjustment		—			(568	)		(621	)
Returns		(1,160	)		952			(1,516	)
Total provision for U.S. product sales allowances and accruals	$	79,351		$	48,350		$	30,438
Total gross U.S. product sales	$	188,146		$	119,712		$	88,725
Total provision for U.S. product sales allowances and accruals as a percent of total gross U.S. product sales		42%			40%			34%

Schedule of customers representing 10% or more of revenues

	Years Ended December 31,
	2014		2013		2012
AmerisourceBergen Drug Corporation		34%		41%		34%
McKesson Corporation		21%		24%		17%
Cardinal Health, Inc.		15%		16%		12%
Takeda Pharmaceuticals Company Limited		11%		11%		31%

Schedule of components of basic and diluted net income (loss) per share

The components of basic and diluted net income (loss) per share were as follows (in thousands, except per share data):

	Years Ended December 31,
	2014		2013			2012
Net income (loss)	$	135,817	$	(9,602	)	$	(16,750	)
Weighted average common shares outstanding (basic)		22,416		21,703			21,392
Effect of dilutive securities (in shares):
Stock options and restricted stock units		520		—			—
Convertible 2.5% senior notes		2,289		—			—
Shares used in calculating dilutive net income (loss) per share		25,225		21,703			21,392
Net income (loss) per share:
Basic	$	6.06	$	(0.44	)	$	(0.78	)
Diluted	$	5.45	$	(0.44	)	$	(0.78	)

Schedule of anti-dilutive securities excluded from computation of diluted net loss per share

The following table sets forth the potential common shares issuable upon the exercise of outstanding options, the vesting of RSUs and warrants (prior to consideration of the treasury stock method), which were excluded from our computation of diluted net income (loss) per share because their inclusion would have been anti-dilutive (in thousands):

	Years Ended December 31,
	2014		2013		2012
Options to purchase shares of common stock		2,708		2,820		2,190
Shares of common stock issuable upon the vesting of restricted stock units		322		465		374
Warrants		7,382		—		—
Total		10,412		3,285		2,564